EPS for Edwards Lifesciences (EW) Expected At $1.11; Home Bancshares (HOMB) Sentiment Is 1.06

April 23, 2018 - By Winifred Garcia

Edwards Lifesciences Corporation (NYSE:EW) Logo

Home Bancshares Inc (HOMB) investors sentiment decreased to 1.06 in Q4 2017. It’s down -2.06, from 3.12 in 2017Q3. The ratio is negative, as 111 funds started new or increased holdings, while 105 sold and decreased their equity positions in Home Bancshares Inc. The funds in our database reported: 108.05 million shares, down from 215.48 million shares in 2017Q3. Also, the number of funds holding Home Bancshares Inc in top ten holdings increased from 2 to 3 for an increase of 1. Sold All: 39 Reduced: 66 Increased: 78 New Position: 33.

Analysts expect Edwards Lifesciences Corporation (NYSE:EW) to report $1.11 EPS on April, 24 after the close.They anticipate $0.17 EPS change or 18.09% from last quarter’s $0.94 EPS. EW’s profit would be $233.68 million giving it 30.88 P/E if the $1.11 EPS is correct. After having $0.94 EPS previously, Edwards Lifesciences Corporation’s analysts see 18.09% EPS growth. The stock decreased 1.06% or $1.47 during the last trading session, reaching $137.09. About 1.54 million shares traded or 13.38% up from the average. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since April 23, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

The stock increased 1.71% or $0.38 during the last trading session, reaching $22.6. About 1.72M shares traded or 98.95% up from the average. Home Bancshares, Inc. (HOMB) has declined 16.14% since April 23, 2017 and is downtrending. It has underperformed by 27.69% the S&P500.

Home BancShares, Inc. operates as the bank holding firm for Centennial Bank that provides commercial and retail banking, and related financial services to businesses, real estate developers and investors, individuals, and municipalities. The company has market cap of $3.93 billion. The Company’s deposit products include checking, savings, and money market accounts, as well as certificates of deposit. It has a 25.39 P/E ratio. The companyÂ’s loan portfolio comprises non-farm/non-residential real estate, construction/land development, residential mortgage, consumer, agricultural, and commercial and industrial loans.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $135.09’s average target is -1.46% below currents $137.09 stock price. Edwards Lifesciences Corp had 109 analyst reports since July 30, 2015 according to SRatingsIntel. On Monday, April 4 the stock rating was maintained by BMO Capital Markets with “Outperform”. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, February 15 report. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. As per Tuesday, April 5, the company rating was downgraded by Northland Capital. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, October 25. The firm has “Buy” rating by BTIG Research given on Monday, April 4. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Outperform” rating given on Wednesday, December 7 by Cowen & Co. The rating was initiated by UBS on Tuesday, September 22 with “Buy”. BMO Capital Markets maintained the shares of EW in report on Wednesday, January 17 with “Buy” rating. SunTrust maintained Edwards Lifesciences Corporation (NYSE:EW) on Tuesday, April 10 with “Buy” rating.

Home Bancshares, Inc. (NASDAQ:Conway, AR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: